Latest revenue
$3.5M
as of 2026-03-31
Latest net income
$-6.5M
as of 2026-03-31
Net margin
-183.3%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ACOG is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $126.5M
- Enterprise value
- $74.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.20×
- Dividend yield
- 0.0%
- 52-wk high
- $11.54
- 52-wk low
- $4.50
- Beta
- —
- Shares out
- 21.8M
5-year trend
What this company does
Alpha Cognition is a biopharma company selling ZUNVEYL, a next-generation acetylcholinesterase inhibitor pill for mild-to-moderate Alzheimer's disease with fewer GI side effects. Revenue comes from U.S. prescription sales targeting nursing homes and long-term care facilities, supplemented by licensing deals like the $44 million CMSI agreement covering Asia, Australia, and New Zealand. The company launched ZUNVEYL on March 19, 2025 and is transitioning from clinical-stage to commercial-stage, targeting operating profitability by 2027 if it shelves pipeline spending.
Generated from ACOG's filing dated 2026-03-31
Key risks
- Single-product dependence: entire commercial future hinges on ZUNVEYL, launched March 19, 2025, into AChEI market dominated by cheap generics like donepezil.
- Reimbursement uncertainty: only 2 of 4 major PBMs signed; $820/month WAC faces formulary, prior-auth hurdles against generic AChEIs costing pennies.
- Cash runway risk: management claims sufficient capital to reach profitability by 2027 only if pipeline development is halted, signaling tight liquidity.
Generated from ACOG's filing dated 2026-03-31
Profitability
Operating margin
-221.7%
97.0%Net margin
-202.2%
97.8%Return on equity
-33.1%
110.5%Return on assets
-25.9%
11.1%Leverage
Debt / equity
0.28×
102.3%Debt / assets
21.6%
80.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $3.5M | +20.7% | $-6.5M | -275.5% | -183.3% |
Q4 2025 2025-12-31 | $2.8M | — | $-7.1M | -22.8% | -255.6% |
Q3 2025 2025-09-30 | $2.8M | — | $-1.3M | +29.1% | -46.4% |
Q2 2025 2025-06-30 | $1.7M | — | $-10.5M | -395.8% | -632.7% |
Q1 2025 2025-03-31 | $2.9M | — | $-1.7M | +65.5% | -58.9% |
Q4 2024 2024-12-31 | — | — | $-5.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-1.9M | +43.1% | — |
Q2 2024 2024-06-30 | — | — | $-2.1M | +24.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ACOG — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$2.9M
Insider selling
$250.0K
Net activity
+$2.6M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ACOG
Institutional value
$676.9K
Total shares held
123.3K
Distinct holders
4
-22 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VILLERE ST DENIS J & CO LLC | 71.2K | $390.7K | -2.7K (-3.7%) | Trimmed |
| 2 | ACT CAPITAL MANAGEMENT, LLC | 51.5K | $282.7K | +0 (+0.0%) | No change |
| 3 | UBS Group AG | 438 | $2.4K | -489 (-52.8%) | Trimmed |
| 4 | Steward Partners Investment Advisory, LLC | 200 | $1.1K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With cash runway predicated on no pipeline advancement, what's your current cash balance and quarterly burn post-ZUNVEYL launch?
- 2
Can you quantify ZUNVEYL scripts and net revenue since the March 19 launch, and formulary wins secured to date?
- 3
Given 55% AChEI discontinuation within a year, what's ZUNVEYL's gross-to-net and pricing versus generic donepezil in LTC formularies?
Refreshed when ACOG files a new report · last from 2026-03-31
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.